Goldman: Biopharma Valuation Discount Hits Extreme Lows; Key Near-Term Catalysts In Focus

Stock volatility across the pharmaceutical sector remains elevated, driven by a flurry of high-impact developments—just in the past week alone:

1. Trump Targets Big Pharma: Slashes Drug Prices With 'Most Favored Nation' Rule, Aims To Cut Out Middlemen